Knowles

Knowles has largely completed its shift to high-margin, non-cyclical specialty components for medical, defense and industrial markets and expects 2025 revenue of around $600 million and EBITDA growth of about 20% with margins moving toward the mid-20% range. The fast-growing Precision Device segment is currently driving organic growth of over 15%; Hearing Health remains a stable-growth business with very high margins. Management cites vertical integration, in-house manufacturing, selective acquisitions (including Cornell Dubilier) and price increases as drivers of margin expansion and is targeting mid-term EBITDA margins of up to 30%. Knowles aims to reduce net debt to around zero by end-2025/early 2026 and plans continued share buybacks within a disciplined capital allocation framework. » More on de.investing.com

Shares of Knowles Corp rose to a record high of $36.42 and, with a market capitalization of about $3.09 billion, are trading near the 52-week high; the stock showed a year-on-year gain of 111.76%. For Q1 2026 the company reported EPS of $0.27 (expectation $0.22) and revenue of $153.1 million (expectation $143.1 million), fueling positive market sentiment. Fundamental data show a Piotroski score of 9, while the RSI signals overbought conditions and InvestingPro rates the stock as overvalued relative to its fair value. » More on de.investing.com

Knowles' shares hit a new 52‑week high at $31.96 and are currently trading around $31.85. Over the past year the stock rose 92.75%, and market capitalization is about $2.69 billion. For Q1 2026 Knowles reported EPS of $0.27 (expectation $0.22) and revenue of $153.1 million (expectation $143.1 million), indicating positive business momentum. Fundamentals are rated strong (Piotroski Score 9, PEG 0.35); analysts have not recently made rating changes. » More on de.investing.com